Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates sold 27,847 shares of the company’s stock in a transaction that occurred on Friday, February 19th. The shares were sold at an average price of $39.23, for a total value of $1,092,437.81. Following the completion of the transaction, the chief executive officer now directly owns 1,161,239 shares of the company’s stock, valued at approximately $45,555,405.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Sharon Mates also recently made the following trade(s):
- On Monday, January 11th, Sharon Mates sold 41,896 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $32.01, for a total transaction of $1,341,090.96.
- On Monday, January 4th, Sharon Mates sold 48,341 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $31.30, for a total transaction of $1,513,073.30.
ITCI opened at $38.97 on Tuesday. The company has a fifty day moving average price of $34.88 and a two-hundred day moving average price of $27.56. Intra-Cellular Therapies, Inc. has a 1-year low of $10.94 and a 1-year high of $40.01. The company has a market cap of $3.12 billion, a P/E ratio of -12.10 and a beta of 1.50.
ITCI has been the topic of a number of recent research reports. Bank of America initiated coverage on shares of Intra-Cellular Therapies in a report on Tuesday, December 15th. They set a “buy” rating and a $40.00 price target on the stock. Zacks Investment Research lowered Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Wednesday, January 13th. Cantor Fitzgerald increased their price target on Intra-Cellular Therapies from $53.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday, December 29th. BTIG Research cut their price objective on Intra-Cellular Therapies from $80.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, November 2nd. They noted that the move was a valuation call. Finally, The Goldman Sachs Group assumed coverage on Intra-Cellular Therapies in a report on Thursday, December 10th. They issued a “buy” rating and a $38.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $45.00.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
Read More: Earnings Reports
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.